1. NOAELs or not in safety pharmacology—An industry survey;Andersen;Journal of Pharmacological and Toxicological Methods,2018
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), guidance for industry;Anon;S7A: Safety Pharmacology Studies for Human Pharmaceuticals,2001
3. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Guidance for Industry;Anon,2005
4. The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s);Dorato;Reg. Tox. Pharmacol.,2005